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Abstract: 
Background: Type I and II inosine monophosphate dehydrogenases (IMPDH) are the targets 
of mycophenolic acid (MPA), a widely used immunosuppressant. The aims of this study 
were: to check the presence of controversial polymorphisms in the IMPDH II gene; to look 
for new ones; and to investigate potential associations between the most frequent SNPs in 
both IMPDH genes and clinical outcome in renal transplant recipients. 
Methods: The DNA and clinical data of 456 patients from two clinical trials were collected. 
We sequenced the IMPDH II gene in 80 patients and we genotyped the 456 patients’ DNA for 
the IMPDH II rs4974081, rs11706052, 787C>T and the IMPDH I rs2278293 and rs2278294 
SNPs, all of which were previously reported to be potentially involved in MPA treatment 
related outcome. We investigated the associations of biopsy proven acute rejection (BPAR), 
leucopenia, CMV infections and other infections with these IMPDH polymorphisms, as well 
as with demographic, biological and treatment data using multivariate analysis. 
Results: Many IMPDH II variant alleles referenced in Genbank were not detected and no new 
polymorphisms were identified. In the whole group of 456 patients, the IMPDH I rs2278294 
SNP was associated with a lower risk of BPAR and a higher risk of leucopenia over the first 
year post-transplantation. No other IMPDH I or IMPDH II polymorphism was significantly 
associated with any clinical outcome. Interestingly, CNI and MPA exposures below the 
therapeutic range increased the risk of BPAR. CMV infection was the factor most closely 
linked with leucopenia, whereas tacrolimus was associated with fewer infections than 
cyclosporine. 
Conclusion: IMPDH II genotyping may not improve MPA treatment outcome over the first 
year post-transplantation, in contrast to MPA and CNI therapeutic drug monitoring and 
IMPDH I genotyping. 
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Introduction 
 
Mycophenolic acid (MPA) is an immunosuppressive drug widely used in liver and 
kidney transplantation [1-3]. Its effect is essentially attributed to the inhibition of type II 
Inosine MonoPhosphate DeHydrogenase (IMPDH) [4-6], a rate-limiting enzyme involved in 
the de novo purine synthesis pathway [7, 8]. Lymphocytes are devoid of the salvage pathway 
that allows other cells to recycle purines, and are therefore dependent on IMPDH II for DNA 
synthesis and GMP/AMP controlled pathways [9]. MPA therapy is not devoid of treatment 
failures and side effects [10-12], which indicates inter-individual pharmacokinetic or 
pharmacodynamic variability. The potential benefit of mycophenolate mofetil (MMF) dose 
adjustment in decreasing the risk of acute rejection is still controversial, as two studies 
yielded divergent results [13, 14]. There have been many attempts to identify 
pharmacogenetic parameters that could be taken into account in order to control MPA 
pharmacokinetic variability, with limited success so far [15, 16]. As IMPDH I and II are the 
target proteins of MPA, polymorphisms in their genes might explain part of the inter-
individual variability in MPA effects [17]. Wang et al. found an association between two 
intronic IMPDH I SNPs (rs2278293 and rs2278294) and the incidence of BPAR in kidney 
transplant recipients, and concluded that these IMPDH I polymorphisms should be considered 
in further pharmacogenetic studies [18]. In a recent study on IMPDH II expression, Vannozzi 
F et al. identified IMPDH II gene as another good candidate for MPA pharmacogenetic 
studies [19]. Several studies demonstrated that both isoforms of IMPDH are transcribed in 
response to T cell activation [11] and that the increase of IMPDH activity is linked to 
activation of both IMPDH isoforms [20-21]. 
The human IMPDH II gene is located on chromosome 3 locus 3p21.2 and is 
approximately 5.2 kb in length (accession number: NC_000003.10). It has 14 exons encoding 
a 1.7 kb mRNA (NM_000884.2) leading to a 514 amino-acid protein of 56 kDa 
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(NP_000875.2) [22]. This protein shares 84% homology with IMPDH I and its exonic 
sequence is highly conserved among species, especially in mammalians [23]. The 3D 
structure has been published, and crucial amino-acids for the enzyme activity (Cys-331, Asp-
364 and Ser-329) and MPA binding site (Ser-276 Thr-333 and Gln-441) have also been 
reported [22, 23]). Polymorphisms in these regions could potentially be linked with inter-
individual variations in MPA effects. A random mutagenesis study has found three IMPDH II 
mutations (L30F/Q227R, A462T and F465S/D470G) conferring resistance to MPA [24]. 
However, none of them have yet been reported in vivo. 
Little is known about the consequences of IMPDH II gene polymorphisms and their 
involvement in patients’ response to MPA. Only two non-synonymous polymorphisms are 
referenced in the NCBI database (the AAG/- rs5848860 deletion and the rs11557540 A/G 
single nucleotide polymorphism) with no frequency mentioned. A recent study [25] based on 
genotyping of more than 400 DNA samples reported no mutated allele for these two 
previously reported polymorphisms (rs5848860 and rs11557540) and suggested these 
reported polymorphisms to be sequencing artifacts. Using in silico techniques, the same team 
predicted a possible effect of a mutation in the promoter region (rs4974081) on IMPDH II 
transcription [25], which has not yet been confirmed by in vitro or clinical studies. Wang J. et 
al. reported the previously non-referenced 787C>T SNP in exon 7, leading to a Leu-Phe 
substitution and a 10-fold decrease in basal enzyme activity in vitro [16]. However, this 
mutation showed a low frequency (~1%) in the population and the authors were not able to 
demonstrate any association between this mutation and clinical outcomes [18].  
Grinyó J. et al recently reported an association of the 3757T>C SNP (rs11706052) in 
intron 7 on the IMPDH II gene with a higher risk of acute rejection in renal transplant 
recipients [15], whereas Wang et al. did not find any association between this SNP and 
clinical outcomes. A recent study in a cohort of 80 renal transplanted patient treated by MPA 
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found increased IMPDH activity in variant carriers of the 3757T>C IMPDH II SNP [26], but 
no association with acute rejection incidence was found, which may have been due to an 
underpowered sample size. 
The goals of the present study in a large group of renal transplants (n=456) receiving 
mycophenolate mofetil in combination with calcineurin inhibitors were to look for possible 
new polymorphisms in exons, the flanking intron-exon regions and the proximal promoter of 
the IMPDH II gene in 80 renal transplant patients and for associations between clinical 
outcomes and the previously reported or new IMPDH polymorphisms, taking in account 
demographic, biological and treatment data as potential confounders.  
 
Material and methods 
 
Patient population: 
This study was conducted in adult, de novo renal transplant patients enrolled in the 
pharmacogenetic substudies of two clinical trials: a first group of 121 (out of 137) patients 
enrolled in of the Apomygre trial (Clinical Trial Registry No. NCT0019967); a second group 
of 335 patients from the international FDCC trial (NCT00166244). Both studies were 
prospective, randomized, open-labeled and aimed to compare concentration-controlled MMF 
with the approved fixed-dose over the first 12 months posttransplantation. All patients signed 
a specific written informed consent for pharmacogenetic investigations. The study design, 
patient populations and primary results were recently reported [13, 14]. Briefly, patients 
enrolled in Apomygre received MMF in combination with cyclosporine, whereas those in 
FDCC were either on tacrolimus or cyclosporine (Table 1). MPA AUC0-12h, the associated 
calcineurine inhibitor (CNI), CNI concentrations, side effects (leucopenia, infection, 
diarrhea), and biopsy proven acute rejection (BPAR) episodes were collected at D7, D14, M1 
M3, M6 and M12 post-transplantation in both trials. Leucopenia was defined as a white blood 
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cell count < 3.10
9
.l
-1
. Infections were defined as clinical infectious syndromes with positive 
identification of an organism by microbiological culture, serology, antigen detection, PCR 
techniques or histology. Patients’ demographic characteristics are reported in Table 1.  
DNA samples: 
In the FDCC study [27], genomic DNA was isolated from 200 μl of EDTA whole 
blood using a total nucleic acid extraction kit (MagNA Pure LC; Roche Diagnostics, 
Mannheim, Germany). In the Apomygre study, genomic DNA was extracted from EDTA-
treated blood using a previously described manual ethanol precipitation method [28]. 
DNA from 80 randomly selected APOMYGRE patients were used for IMPDH II 
sequencing. The genomic DNA samples from 121 APOMYGRE and 335 FDCC patients 
were genotyped and used for the pharmacogenetic association study. 
IMPDH II sequencing: 
To tentatively identify novel IMPDH II mutations, 10 targets covering the proximal 
promoter, 14 exons and intron/exon flanking regions from 80 patients DNA samples were 
sequenced. Table 2 lists the SNPs identified. Ten genomic DNA regions (target 1 to 10) 
covering the proximal promoter region, the 14 exons and the flanking intron-exon regions of 
the IMPDH II gene were PCR-amplified using the AmpliTAQ gold PCR master mix (Applied 
Biosystems, Courtaboeuf, France) (covered regions are reported in supplemental Table 1). 
Reactions were carried out in a final volume of 100 µl using 150 ng genomic DNA and 10 
µM of reverse and forward primers, designed using the Primer3 website 
(http://frodo.wi.mit.edu/) and reported in supplemental Table 1. Amplification consisted of an 
initial denaturation for 6 minutes at 95°C followed by 35 cycles of denaturation at 95°C for 15 
seconds, annealing at 60°C for 15 seconds and extension at 72°C for 1 minute. Terminal 
elongation was performed at 72°C for 7 minutes. The PCR-amplified products were purified 
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using the QiaVac96 kit (Qiagen, Courtaboeuf, France) and forward sequenced using the 
Bigdye terminator v1.1 kit (Applied Biosystems) according to the manufacturers’ procedures. 
All the potential SNPs were confirmed by reverse sequencing. The extension products were 
purified using a standard Ethanol/EDTA/sodium acetate precipitation procedure and the 
nucleotide sequences determined on an ABI 3100 automated sequencer (Applied-
Biosystems). The Sequencer v4.8 program (Gene Codes Corp. Ann arbor, MI, US) was used 
for data processing using the IMPDH II reference sequence (Genbank NC_000003.10) for 
automatic alignment. All SNPs and unclear regions were visually checked. 
Genotyping assays: 
The IMPDH II rs11706052 and 787C>T SNPs were genotyped in patients whose 
DNA had not been sequenced at the previous step. The previously reported rs4974081, 
rs2278293 and rs2278294 SNPs were genotyped in all 456 patients because IMPDH II 
rs4974081 was out of our sequencing coverage and both rs2278293 and rs2278294 are 
located on the IMPDH I gene. Genotyping was performed using validated TaqMan allelic 
discrimination assays on an ABI PRISM 7000 Sequence Detection System (Applied 
Biosystems), using the manufacturer protocol. 
Statistical analyses: 
 Deviation from the Hardy-Weinberg equilibrium was investigated for each SNP 
separately using the Fisher exact test. Statistical analyses were performed using R software 
version 2.10.1 (R foundation for statistical computing, http://www.r-project.org). Each 
clinical outcome criterion (BPAR, CMV infections, other infections and leucopenia episodes 
occurring over the first year post transplantation) was used in turn as the dependent variable 
for stepwise logistic regression analysis using the “Epicalc” R package. Different genetic 
models (co-dominant, dominant, recessive and log-additive) were tested using the 
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“SNPassoc” R package. The log-addidive model was retained for all the dependent variables 
on the basis of the lowest Akaike criterion. Patients’ genotypes, sex, age, MPA inter-dose area 
under the concentration-time curve (AUC0-12h), the associated CNI and its representative 
blood levels (C2h for cyclosporine, C0 for tacrolimus), were used as independent variables. In 
addition, CMV infections were considered as an independent variable for the multivariate 
regression analysis considering leucopenia as the dependant variable. The CNI concentration 
and MPA AUC0-12h values used were those closest to the event or, when the dose 
administered or patient’s exposure might have been influenced by the event, just prior to it. 
Concentration values in the stable period (M6-M12) were used when no events occurred. 
Patients were divided into the following categorized groups: below (group 1), within (group 
2), or above (group 3) the target range for either CNI concentration (CNI concentration 
groups) or MPA AUC0-12h (MPA AUC groups). Target ranges were 30 to 60 mg.h/l for MPA 
AUC0-12h; 1300-1500 (D7-M1), 1100-1300 (M1-M3), 800-1100 (M3-M6) and 700-900 µg/l 
(M6-M12) for cyclosporine C2h [13]; 10-15 µg/l (D7-M3) and 5-15 µg/l (M3-M12) for 
tacrolimus C0 [29]. The final multivariate model was determined by stepwise regression. 
Variables with p values > 0.20 were not included into the final model; p values < 0.05 in the 
final model were considered as significant. Linkage disequilibrium estimation and haplotype 
analysis were performed using the THESIAS program (http://genecanvas.ecgene.net).  
Results 
IMPDH II polymorphisms: 
Within exonic regions, no SNP was detected. Specifically, no variant allele for the two 
non-synonymous (rs11557540 and rs5848860) or the seven synonymous (rs11557543, 
rs11557547, rs11557541, rs11557545, rs11557542, rs11557544 and rs11557546) SNPs 
referenced in Genbank (http://www.ncbi.nlm.nih.gov/SNP; June 2009) were found. Similarly, 
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the 787 C>T (Leu236Phe) and 417 C>T SNPs previously reported by Wang et al. [16]  could 
not be found in these 80 samples. Within the intronic regions sequenced, the SNPs referenced 
in Genbank were not found either, except for the rs11706052 SNP (i.e., IVS7+10T>C or 
3757T>C; Table 2), detected in 9.3% of the sequenced alleles (Table 2). In addition, we 
observed, although at low frequencies, 3 previously reported intronic SNPs (IVS1-162C>T: 
1.2%; IVS1+91 T>G: 0.6%; and IVS12-23C>T: 2.5%; Table 2). The IVS4+197 C>T and 
IVS5-62 G>A SNPs reported by Wang et al. were located out of our target boundaries and the 
IVS8-7G>A SNP was not present in the samples analyzed. No other SNP was found in the 
untranslated (intronic, proximal promoter and 5’/3’ UTR) regions sequenced. 
The minor rs4974081 allele located in the IMPDH II distal promoter region was 
genotyped and found at an allelic frequency of 24% in our 456 patients (Table 3). The 
intronic 3757T>C (rs11706052) SNP detected by gene sequencing was further investigated in 
the remaining patients by genotyping. The frequency of its variant allele was 9% (Table 3). 
No variant 787C>T (Leu236Phe) allele was found in the group of 456 patients (Table 3). No 
linkage disequilibrium was found between IMPDH II rs4974081 and rs11706052 SNPs (r² = 
0.02). 
IMPDH I polymorphisms: 
For the IMPDH I rs2278293 and rs2278294 SNPs, the minor allele frequencies were 46% 
and 36%, respectively (Table 3). The allelic distributions of all the SNP detected were in the 
Hardy-Weinberg equilibrium. The SNPs were in strong linkage disequilibrium (D’=0.78; 
r
2
=0.41) leading to 4 haplotypes with the following frequencies: G-G (0.50); G-A (0.04); A-G 
(0.14), A-A (0.32). 
For those previously reported, the allelic frequency found here was consistent with the 
literature: rs4974081, 21% in Caucasians [25]; 3757T>C (rs11706052) 7-10.2% [15, 16]; 
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787C>T (Leu236Phe) < 1% [16, 26] ; rs2278293 42.7% ; and rs2278294 40.6% [18]. It is 
noteworthy that the patients’ ethnicity or the allelic distribution between ethnic 
subpopulations was not mentioned in these last four papers. 
Association between clinical outcome and genetic, demographic and pharmacologic 
parameters: 
 
No association was found between the four tested clinical outcomes and any of the 
IMPDH II genotypes tested. Neither variants of the distal promoter (rs4974081) nor of the 
3757T>C (rs11706052) SNPs were significantly associated with an increased risk of side 
effects or acute rejection (OR for BPAR was 0.66 (95% CI [0.39-1.13]; p = 0.13) for 
rs4974081 variant allele carriers, and 0.89 (95% CI [0.44-1.78]; p = 0.74) for rs11706052 
carriers). The IMPDH I rs2278293 variant allele was not significantly associated with any 
tested outcomes either. The final regression model using acute rejection (BPAR) as the 
dependent variable included IMPDH I rs2278294, MPA AUC0-12h and CNI blood levels as 
significant factors (Table 4). The risk of BPAR was lower for the rs2278294 variant allele 
carriers, with a gene-additive effect (OR 0.54 [0.34-0.85]; p = 0.0075). Patients whose 
exposure was below the target range for both immunosuppressive drugs presented a 
significantly higher risk of acute rejection than patients within or above the target range for at 
least one of the drugs (OR: 2.22, 95% CI [1.20-4.11]; p = 0.0109 and OR: 2.27, 95% CI 
[1.272-4.06]; p = 0.0056 for MPA AUC0-12h and CNI blood level respectively) (Table 4). 
Leucopenia was significantly associated with IMPDH I rs2278294, the type of CNI used, 
their categorized blood levels and CMV infections. However, the CNI type may be a 
confounding factor, as it showed a significant interaction with CMV (p = 0.0369). The 
association with IMPDH I rs2278294 showed an additive risk for each variant allele carried 
(OR 1.66, 95% CI [1.11-2.48]; p = 0.0139) (Table 4).  
11 
 
Haplotype analysis of IMPDH I showed no significant association with the clinical 
outcomes.  
Discussion 
 
We did not discover any new IMPDH II polymorphism in the 80 patients whose DNA was 
sequenced. In addition, we did not observe the previously reported, non-synonymous IMPDH 
II polymorphisms rs11557540, rs5848860 and 787C>T. The first two mutations were already 
indicated as potential sequencing errors by Mohamed et al. [25] who studied a cohort of more 
than 400 patients, whereas the third (787C>T) polymorphism was found at a low frequency 
(1% or less) by Wang et al. in two different studies [16, 18]. However, we did not find this 
last variant allele either when genotyping our 456 DNA samples. This difference may be due 
to the different ethnical origins of the populations studied. Even though Wang et al. reported 
that the Leucine to Phenylalanine amino acid change resulting from this SNP induced a 
drastic decrease in IMPDH II catalytic activity [16], they also wrote in a second paper that a 
putative association with leucopenia would be difficult to prove due to its very low frequency 
[18]. Furthermore, such a rare allele would probably not significantly contribute to clinical 
management of the MMF benefit/risk balance.  
The present sequencing study did not retrieve any mutated allele of the IMPDH II intronic 
SNPs listed in GenBank, except for rs11706052 (3757T>C) which was present at a frequency 
similar (9% of our 456 patients) to those reported by Grinyo et al. [15] and Wang et al. [16]. 
In our cohort, this SNP was not significantly associated with BPAR, which is consistent with 
the results previously reported by Wang et al. [18] who found no association in 191 kidney 
transplant recipients using univariate analysis. However, Grinyo et al [15] did find a 
significant association between the 3757T>C SNP and BPAR at 3 and 12 months post-
transplantation in 237 patients of the CAESAR study. They used multivariate logistic 
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regression but only considered a few demographic covariates (age, sex, treatment groups – 
cyclosporine standard dose, low-dose or withdrawal- and donor type), but not MPA dose (that 
was significantly linked with BPAR in their study) or MPA exposure. They also admitted that 
they had very few variant allele carriers and that they had no mechanistic explanation for this 
association. The present study has the largest group of patients prospectively followed for one 
year post-transplantation so far, and used multivariate logistic regression considering many 
possible confounders. We were not able to confirm the association between this genotype and 
acute rejection.  
We also found that this 3757T>C SNP was not associated with leucopenia (which was 
consistent with Wang et al.’s results) [18], nor with CMV infections or other infections, 
which were not tested in the other two studies. A recent paper [26] reported a higher IMPDH 
activity in carriers of the variant 3757T>C SNP, without any association with clinical 
outcomes. As we did not measure IMPDH activity in the present patient cohort, we were 
unable to check the functional consequence of this polymorphism. 
We were also interested in the promoter variant rs4974081 for which an effect on IMPDH 
II transcription and thus possibly on MMF effects was forecasted in silico [25]. The variant 
allele was present in 25% of our 456 patients, but no statistically significant association was 
found with any clinical outcome tested. In vitro studies of IMPDH II transcription may give 
more information about the potential influence of this promoter mutation. 
We found three IMPDH II intronic SNPs, which were previously reported by Wang et al 
[16] at the same low frequencies. These SNPs showed no significant association with patient 
outcomes. Although the study may have been underpowered to find any significant 
association with these rare mutated alleles, it is less likely that intronic SNPs have a large 
influence on MPA pharmacodynamics. 
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We also investigated two IMPDH I polymorphisms (rs2278293 and rs2278294) which 
were previously reported to be associated with a decreased risk of BPAR [18]. No association 
with either BPAR or other tested outcomes was found for the rs2278293 variant in our large 
sample of patients.  This discrepancy with Wang et al. is not explained by the fact that we did 
not group heterozygous and homozygous variant carriers (51% and 20% of patients, 
respectively) to perform our analyses, because when we did there was no significant 
association between the rs2278293 variant and BPAR either (data not shown). On the other 
hand, we did find a significant, protective effect on BPAR of the rs2278294 variant allele as 
compared to the wild-type allele (log-additive model; OR 0.54 95% CI [0.34-0.85]; p = 
0.0075; Table 4). Nevertheless, no explanation on the mechanism behind this decreased risk 
of BPAR with an IMPDH I intronic SNP could be inferred. The mutant allele carriers also 
had a 1.6-fold increased risk of leucopenia, again with a gene-dose effect. The fact that BPAR 
and leucopenia are inversely associated to the same rs2278294 SNP reinforces the pertinence 
of this finding. A factor favoring low lymphocyte levels, sometimes leading to leucopenia 
episodes, is expected to protect the patient from developing an immunological reaction 
against the allograft. 
One limitation of this study is that we missed information about the patients’ ethnicity. 
This is partly due to the fact that the APOMYGRE study was conducted in France, where it is 
not legally possible to ask patients about their ethnic origins, unless it is the main aim or a 
main determinant of the study and provided one obtains a special authorization from the 
ministry of health. However, all patients enrolled in this sub-study were recruited in Europe, 
which suggests that a vast majority were of European descent, although this cannot be 
ascertained.  
When combined with MPA, cyclosporine was associated with more frequent side effects 
(leucopenia, CMV and other infections) than tacrolimus, with no difference in acute rejection 
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incidence. Nevertheless, the association between CNI type and infections could be biased by 
the fact that all tacrolimus co-treated patient were enrolled in the FDCC trial where reporting 
infections could have been slightly different from the APOMYGRE trial.  
Currently, the benefit of MPA TDM in transplant recipient is still under debate, as 
highlighted in a recent review by Knight & Morris [30]. Many retrospective studies found 
significant relationships between MPA AUC0-12h and BPAR or side effects in various types of 
populations [31-35], but the few prospective studies lead to diverging conclusions. The FDCC 
study found no statistically significant differences in outcome between the fixed-dose group 
and the dose-adjusted group [14], whereas the Apomygre trial did [13]. In the current 
retrospective study based on patients from these two trials we found statistically significant 
evidence that being in the target range for both the CNI (whether cyclosporine or tacrolimus) 
and MPA strongly protected against acute rejection, with no increased risk of side effects. 
Conclusions 
 
We did not find new variant alleles in the IMPDH II gene when sequencing DNA from 80 
patients, nor associations between the known IMPDH II polymorphisms and clinical outcome. 
We found a significant association of the IMPDH I rs2278294 SNP with BPAR and 
leucopenia, but the previously reported association between IMPDH I rs2278293 and 
outcomes was not confirmed.  MPA AUC0-12H < 30 mg.h/L was significantly associated with 
an increased risk of BPAR, while the nature of and the exposure to the associated CNI were 
associated with BPAR, and leucopenia.  
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Table 1: demographic characteristics of the studied patients enrolled either in the Apomygre 
or FDCC trials.  
 Apomygre (n=121) FDCC (n=335) Total (n=456) 
Sex    
Female 42 129 171 
Male 79 206 285 
Age (years) 
49.5 ± 13.7 48.6 ± 13.0 48.8 ± 13.2 
Co treatment    
Cyclosporine 121 156 277 
Tacrolimus 0 179 179 
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 Table 2: Summary of all known IMPDH II (NC_000003.10) polymorphisms and their 
localization. Positions are presented relatively to ATG set as +1.  
Position (ATG as +1) Genebank 
accession 
number 
Other names Synony- 
mous 
(Yes/No) 
Found in this 
study (minor  
allele 
frequency)* 
# - 3624 A>G / Promoter
1 rs4974081  NA°  NA  Out of bounds  
# - 162 C>T / Promoter
2
  NA  IVS1 - 162 C>T  NA  Yes (1.2%)  
# 189 T>G / Intron 1
2
  NA  IVS1+91 T>G NA  Yes (0.6%)  
# 834  C>T / Exon 3  rs11557543  NA  Yes No  
# 863  A>G / Exon 3  rs11557547 NA  Yes  No  
# 1049 C>T / Exon 4  rs11557541  NA  Yes  No  
# 1331 C>T / Intron 4
2
  NA  IVS4+197 C>T  NA  Out of bounds  
# 1373 G>A / Intron 4
2
  NA  IVS5-62 G>A  NA  Out of bounds  
# 1455  C>T  / Exon 5  rs11557545  NA  Yes  No  
# 1527 C>T / Exon 5
2
  NA  417 C>T Phe139Phe  Yes  No  
# 1570 T>C / Exon 5  rs11557542  NA  Yes  No  
# 2565 C>T / Exon 7  rs11557544  NA  Yes  No  
# 2632 C>T / Exon 7
2
  NA  787 C>T  Leu236Phe N (Leu>Phe)  No  
# 2674 T>C / Intron 7
2,3 rs11706052  IVS7+10 T>C/3757 T>C NA  Yes (9.3%)  
# 2735 G>A / intron 7
2 NA  IVS8-7G> A NA No  
# 2936 C>G / Exon 9 rs11557546 NA  Yes  No  
# 4413 A>G / Exon 11
1
  rs11557540  NA  No 
(asp>Gly)  
No  
# 4526 C>T / intron 11
2
  NA  IVS12-23 C>T  NA  Yes (2.5%)  
# 4833 AAG/- / Exon 13
1
  rs5848860  NA  No  No  
# 4965 C>T / Exon 14 rs104981  NA  Yes  No  
*Calculated from sequencing data. °NA= not applicable 
1
Mohamed et al. 
2
Wang et al. 
3
Grinyo et al. 
18 
 
Table 3. Observed frequencies of the genotyped IMPDH I and IMPDH II SNPs.  
SNP Genotype  Frequencies (n=456) MAF* 
IMPDH I gene    
rs2278293 Homozygous wt (GG) 28.9%  
 Heterozygous (AG) 51.1% 46% 
 Homozygous var (AA) 20.0%  
rs2278294 Homozygous wt (GG) 41.2%  
 Heterozygous (AG) 45.6% 36% 
 Homozygous var (AA) 13.2%  
 
IMPDH II gene 
 
 
 
rs4974081 Homozygous wt (AA) 56.4%  
 Heterozygous (AG) 37.9% 24% 
 Homozygous var (GG) 5.7%  
rs11706052 Homozygous wt (TT) 82.1%  
 Heterozygous (TC) 17.4% 9% 
 Homozygous var (CC) 0.4%  
787C>T Homozygous wt (CC) 100.0%  
 Heterozygous (CT) 0% 0% 
 Homozygous var (TT) 0%  
(*MAF = Minor allele frequency; wt = wild type; var = variant) 
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Table 4: Results of multivariate, stepwise logistic regression. Only the significant dependent 
variables kept in the final model are shown. 
Variable Category Adjusted OR 95%CI P Value 
1. Leucopenia over the first year post-transplantation 
CMV 
Yes 6.06 [3.03-12.11] < 0.0001 
 No - - - 
CNI Cyclosporine - - - 
 Tacrolimus 0.49 [0.24-1.00] 0.0503 
CNI groups 1. Below TR 0.37 [0.18-0.74] 0.0052 
 2. Within TR 
Grouped - - - 
 3. Above TR 
IMPDH I  G (WT)  - - - 
rs2278294 A  1.66 [1.11-2.48] 0.0139 
Interaction 
CNI*CMV 
    0.0369 
2. CMV infections 
Age Per year increase 1.02 [1.01-1.04] 0.0330 
Sex Female - - - 
 Male 0.61 [0.38-0.99] 0.0467 
CNI Cyclosporine - - - 
 Tacrolimus 0.33 [0.19-0.57] < 0.0001 
3. Other Infections 
CNI Cyclosporine - - - 
 Tacrolimus 0.22 [0.13-0.37] < 0.0001 
4. BPAR 
AUC MPA groups 1.Below TR 2.22 [1.20-4.11] 0.0109 
2.Within TR 
Grouped - - - 
 3.Above TR 
CNI groups 1. Below TR 2.27 [1.27-4.06] 0.0056 
 2. Within TR 
Grouped - - - 
 3. Above TR 
IMPDH I  G (WT)  - - - 
rs2278294 A  0.54 [0.34-0.85] 0.0075 
(TR = therapeutic range, WT = wild type) 
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Supplemental Table 1: Primers, sequences and coverage of IMPDH II proximal promoter, 
exons, and flanquing intronic/exonic regions. 
Primer 
name 
Sequence (5’ to 3’) 
IMPDH II gene coverage (bp) 
Target n°1 
 
T1Left GGCTTGGACTGTGAAAAGAAA 
Proximal Promoter (-500 to -160) 
T1Right CCGCGCCAATATAAACCA 
Target n°2 
 
T2Left CGTCTCTTTATTTTGGGGAGGA Proximal Promoter + 5’UTR + Exon 1 + flanking region 
Intron1/Exon1 (-160 to 270) T2Right CATGTGTCTGGAGCATGGAA 
Target n°3 
 
T3Left GAGATTCCATGCTCCAGACAC Flanking region Intron1/Exon1 + Exon 1 + Flanking 
region Exon 1/Intron 2 (440 to 620) T3Right GAAAGCATCCCTTACACCTCA 
Target n°4 
 
T4Left ATCACCAGATTGGGCTTGG Flanking region Intron 2/Exon 3 &  Exon 4/Intron 5  + 
Exon 3 + Intron 3 + Exon 4 + (730 to 1110) T4Right GACCAAATCACACCAACACATC 
Target n°5 
 
T5Left GTTGGTGTGATTTGGTCTTGTG Flanking region Intron 4/Exon 5 & Exon 5/ Intron 5 
+ Exon 5 (1400 to 1860) T5Right CAGTATGATTGAGTGAGGGATGAG 
Target n°6 
 
T6Left TCAGCTACTTGGGAAGGAAAGA Flanking region Inton 5/Exon 6 + Exon 6 to 8 + intron 7 
and 8 (2280 to 2830) T6Right CTTACCCACTCCCACCACAC 
Target n°7 
 
T7Left TCCAAAGATGCCAAGAAACA Flanking region Intron 7/Exon 8 & Exon 9/Intron 9 + 
Exon 8 + Intron 8 + Exon 9 (2700 to 3160) T7Right GCAGAGCAGGAGCAAGAAGG 
Target n°8 
 
T8Left AGCAGCCATCCCAGACAC Flanking region Intron 9/Exon 10 + Exon 10 (3770 to 
4220) T8Right CTTGCCTGTCCCACCTGAA 
Target n°9 
 
T9Left CATGTGTTCCTCCATCTCAACA Exon 10 + Flanking region Exon 10/Intron 11 + Intron 
10 & 11 + Exon 11 & 12(4090 to 4640)  T9Right ATGCCAGCAATCAGGTAAGG 
Target n°10 
 
T10Left ATTTGTCCCTTACCTAGATTGCT Exon 12 to 14 + intron 12 & 13 + 3’UTR (4650 to 5110) 
T10Right CAGGAGGAACTTTTTGGACCTGGAA 
 
